Human bone marrow derived mesenchymal stem cells (MSC) pretreated with interleukin-17A (IL-17A) represent a novel immunomodulatory strategy and an alternative to interferon-gamma (IFN- γ) treatment of MSC in enhancing MSC immunosuppression of T cells [1].

Interleukin-17A (IL-17A) pretreated MSCs are more immunosuppressive with minimal changes in immunogenicity in vitro. Here, we demonstrated that administration of IL-17A-pretreated MSCs resulted in significantly lower acute tubular necrosis scores, serum creatinine, and BUN of mice with IRI-AKI, compared with the administration of MSCs.

Nov 11, 2021 · Interleukin (IL)-17A, produced in the early phase of inflammation, influences the fate of osteoprogenitors. Due to their inherent capacity to differentiate into osteoblasts, mesenchymal stem/stromal cells (MSCs) contribute to bone healing and regeneration.

Jul 18, 2014 · In this study, we examined the effect of IL-17 on mesenchymal stem cells (MSCs) under the influence of inflammatory cytokines. Ironically, IL-17 dramatically enhanced the immunosuppressive...

Apr 1, 2018 · IL-17A is an alternative cytokine to preactivate MSC. IL-17A enhances the therapeutic efficacy of MSC for renal diseases. Mesenchymal stem cells (MSCs) have unique immunomodulatory, anti-inflammatory, and reparative properties beneficial for kidney transplantation cellular therapy.

IL-17A is an alternative cytokine to preactivate MSC. IL-17A enhances the therapeutic efficacy of MSC for renal diseases. Mesenchymal stem cells (MSCs) have unique immunomodulatory, anti-inflammatory, and reparative properties beneficial for kidney transplantation cellular therapy.

The article by Bai et al. is an in vivo proof-of-concept study that interleukin-17A (IL-17A) enhances the immunosuppressive, tolerance-promoting, and renoprotective properties of MSC. IL-17A is an alternative cytokine to preactivate MSC.

proof-of-concept study that interleukin-17A (IL-17A) enhances the immunosuppressive, tolerance-promoting, and renoprotective properties of MSC. IL-17A is an alternative cytokine to preactivate MSC. IL-17A enhances the therapeutic efficacy of MSC for renal diseases. Kidney International (2018) 93, 771–773; https://doi.org/10.1016/j.kint.2017. ...

Feb 6, 2021 · We investigated spinal soft tissue and bone mesenchymal stem cell (MSC) responses to IL-17A and TNF, including their osteogenesis, adipogenesis, and stromal supportive function and ability to support lymphocyte recruitment.

Human mesenchymal stem cells pretreatment with IL-17A (MSC-17) potently enhances T cell immunosuppression but not their immunogenicity, in addition to avidly promoting the induction of suppressive regulatory T cells.